Gestational diabetes mellitus (GDM) affects approximately one in seven pregnancies worldwide, increasing risks of preterm birth, cesarean delivery, and long-term metabolic disease for both mother and child. The standard approach, dietary modification, glucose monitoring and insulin when necessary, is reactive rather than preventive. An underlying trigger that could be addressed early has remained elusive.
A new study published in Nature Communications points to a surprising candidate: the oral microbiome.
Researchers from China Agricultural University, Chongqing Medical University, and collaborating institutions have found that GDM is associated with a progressive shift in the oral bacterial community, from a Streptococcus-dominated balance toward a Prevotella- and Porphyromonas-enriched dysbiosis, and that this shift may directly contribute to hyperglycemia through an inflammation-mediated pathway.
The cohort
The team longitudinally profiled the oral microbiome of 534 pregnant women drawn from over 2,500 volunteers, tracking bacterial composition across trimesters. Women who developed GDM showed a characteristic dysbiotic trajectory: loss of commensal Streptococcus species and enrichment of pro-inflammatory Prevotella and Porphyromonas, the same genera implicated in periodontal disease.
This oral dysbiosis was accompanied by elevated systemic inflammatory markers, particularly IL-17 and IL-1β, and reduced levels of glucagon-like peptide-1 (GLP-1), an incretin hormone that stimulates insulin secretion. The authors propose a causal chain: dysbiosis-driven periodontal inflammation triggers systemic IL-17 and IL-1β, which in turn suppress GLP-1 and insulin production, exacerbating hyperglycemia.
The mouse model
To test causality, the team transplanted GDM-associated dysbiotic oral microbiota into mice. The recipients developed the full pathway of periodontal inflammation, elevated IL-17/IL-1β, suppressed GLP-1/insulin and worsened glucose tolerance. Conversely, transplanting Streptococcus-dominated microbiota from healthy pregnant women reversed the phenotype, attenuating inflammation and restoring glycemic control.
The clinical trial
The translational arm of the study was a double-blind randomized controlled trial involving 40 pregnant women with GDM. The intervention was topical gingival docosahexaenoic acid (DHA), an omega-3 fatty acid that the team found to be depleted in the saliva of GDM patients. In vitro, DHA selectively suppressed the dysbiosis-associated pathogens Prevotella and Porphyromonas while sparing commensal Streptococcus.
After six weeks of daily gingival application, the DHA group showed improved probing depth (a measure of periodontal health) and a significantly attenuated rise in fasting glucose: median change of 0.10 mmol/L in the DHA group versus 0.27 mmol/L in the placebo group.
Caveats
The clinical findings remain preliminary. The sample size of 40 is small, and the outcome measure, fasting glucose, is a surrogate endpoint. The authors explicitly state that the results require validation in larger trials with broader glycemic endpoints, including oral glucose tolerance tests and HbA1c.
The mechanistic pathway, dysbiosis → IL-17/IL-1β → GLP-1/insulin suppression → hyperglycemia, is supported by the mouse experiments but has not been fully confirmed in humans. Whether topical gingival DHA is a practical, scalable intervention for GDM management will depend on replication in multi-center trials.
What it means
If confirmed, the findings would represent a genuinely new approach to GDM: a non-invasive, locally administered nutritional intervention targeting the oral microbiome rather than systemic glucose metabolism. DHA is already widely used as a prenatal supplement for fetal neurodevelopment; reformulating it for topical gingival delivery in pregnancy would face low regulatory and safety hurdles.
The study also adds to the growing evidence that the oral microbiome, not just the gut microbiome, plays a systemic role in metabolic health, and that periodontal health in pregnancy may matter for metabolic outcomes in ways that have been underappreciated.
Trial registration: ChiCTR2400080741.
Source
Gao, S., Yin, N., Wei, R., et al. “Oral microbiome modulation mitigates hyperglycemia exacerbation in gestational diabetes mellitus.” Nature Communications (2026). DOI: 10.1038/s41467-026-74917-w